|
May 20
|
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
|
|
May 15
|
ASX Growth Stocks With High Insider Ownership To Watch
|
|
Apr 17
|
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
|
|
Apr 16
|
3 ASX Growth Companies With Up To 23% Insider Ownership
|
|
Apr 15
|
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
|
|
Apr 14
|
Clarity Pharmaceuticals And 2 Other ASX Penny Stocks To Watch
|
|
Mar 5
|
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
|
|
Feb 19
|
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
|
|
Dec 22
|
First patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
|
|
Nov 30
|
Registrational Phase III CLARIFY trial in prostate cancer commences
|
|
Nov 30
|
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
|
|
Nov 29
|
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
|
|
Oct 26
|
Clarity and PSI kick off SAR-bisPSMA Phase III
|